Features Partner Sites Information LinkXpress
Sign In
Demo Company

Toolkit Designed to Expand Resources for Genomic Research

By BiotechDaily International staff writers
Posted on 28 Aug 2013
Print article
Image: The PhenX toolkit homepage. Use of PhenX toolkit measures helps researchers understand the relationships between genetics, health, disease, and environment (Photo courtesy of PhenX Toolkit, RTI).
Image: The PhenX toolkit homepage. Use of PhenX toolkit measures helps researchers understand the relationships between genetics, health, disease, and environment (Photo courtesy of PhenX Toolkit, RTI).
Use of a new genotype/phenotype resource should help researchers better determine the links between genetics, disease, health, and the environment.

As part of a new award from the US National Human Genome Research Institute (Bethesda, MD, USA), RTI International (Research Triangle Park, NC, USA) will expand the PhenX Toolkit, a web-based resource that supports collaborative genomics and biomedical research.

The goals of the four-year, USD 5.3 million award, the genomic resource grant for PhenX Toolkit include updating and expanding the Toolkit, integrating Chinese and Spanish translations of PhenX protocols and mapping PhenX variables to all completed studies in the database of genotypes and phenotypes (dbGaP).

“This award gives the PhenX team the opportunity to address the evolving needs of the scientific community by enhancing the content and features of the Toolkit,” said Carol M. Hamilton, PhD, director of bioinformatics at RTI and PhenX lead investigator. “The use of PhenX measures increases the opportunities for researchers to combine or compare their findings, thus increasing the impact of each individual study.”

The PhenX Toolkit, a web-based catalog of 339 well-established measures of phenotypes and exposures, combines data from a range of research and allows investigators to enlarge a study design beyond the basic research focus. Enhancements to PhenX measurements will increase the overall impact of individual studies by making it easier to compare and combine data.

“The PhenX Toolkit is a great resource for investigators who would like to strategically expand their study design by adding a few standard measures,” Dr. Hamilton said. “Because common, complex diseases share many risk factors, identification of these factors increases with the use of common measures in research studies.”

PhenX is driven by the scientific community and decisions are reached using an established consensus process. Since 2007, the RTI-led PhenX project has engaged working groups of experts to select high-priority measures and a steering committee to provide guidance and policymaking decisions.

The PhenX Toolkit currently has more than 1,100 registered users and is publically available at no cost online (please see Related Links below).

Related Links:

RTI International
PhenX Toolkit

Print article



view channel
Image: Left: Green actin fibers create architecture of the cell. Right: With cytochalasin D added, actin fibers disband and reform in the nuclei (Photo courtesy of the University of North Carolina).

Actin in the Nucleus Triggers a Process That Directs Stem Cells to Mature into Bone

A team of cell biologists has discovered why treatment of mesenchymal stem cells (MSCs) with the mycotoxin cytochalasin D directs them to mature into bone cells (osteoblasts) rather than into fat cells... Read more


view channel

Molecular Light Shed on “Dark” Cellular Receptors

Scientists have created a new research tool to help find homes for orphan cell-surface receptors, toward better understanding of cell signaling, developing new therapeutics, and determining causes of drug side-effects. The approach may be broadly useful for discovering interactions of orphan receptors with endogenous, naturally... Read more


view channel

Purchase of Biopharmaceutical Company Will Boost Development of Nitroxyl-Based Cardiovascular Disease Drugs

A major international biopharmaceutical company has announced the acquisition of a private biotech company that specializes in the development of drugs for treatment of cardiovascular disease. Bristol-Myers Squibb Co. (New York, NY, USA) has initiated the process to buy Cardioxyl Pharmaceuticals Inc. (Chapel Hill, NC, USA).... Read more
Copyright © 2000-2015 Globetech Media. All rights reserved.